| 靶点: |
Nox1 Nox2 Nox4 |
| 体外研究: |
APX-115 (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression in the mouse podocyte cell line. In the kidney, APX-115 attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes. |
| 体内研究: |
APX-115 (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice.
APX-115 treatment decreases the urinary excretion of albumin and plasma creatinine levels. |
| 溶解性: |
DMSO : 100 mg/mL (316.66 mM; Need ultrasonic) |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 备注: |
1. Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8(43):74217-74232.
2. Cha JJ, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 2017 Apr;97(4):419-431. |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.167 ml |
15.833 ml |
31.666 ml |
| 5 mM |
0.633 ml |
3.167 ml |
6.333 ml |
| 10 mM |
0.317 ml |
1.583 ml |
3.167 ml |
| 50 mM |
0.063 ml |
0.317 ml |
0.633 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |